top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

Dear Editor, We thank Dr Martinez-Martin et al. for their interest in our article.1 In their letter, the authors question if SGLT1 has no compensatory role during the inhibition of SGLT2 We referred ...

European Heart Journal - Cardiovascular Pharmacotherapy, Correspondence, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 103014 bytes
Ehjcvp

Dear Editor, We thank Dr Martinez-Martin et al. for their interest in our article.1 In their letter, the authors question if SGLT1 has no compensatory role during the inhibition of SGLT2 We referred ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Anne E. de Leeuw, Rudolf A. de Boer

Date : 30/05/2016 Item size : 103449 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes